INGREZZA clinical patient cases in Huntington’s disease chorea
See results with INGREZZA from the KINECT-HD pivotal studya
These videos demonstrate the effect of treatment of Huntington’s disease (HD) chorea as seen in the INGREZZA® (valbenazine) capsules phase 3 clinical program.
Leah
Age:
- 45
CAG repeat length:
- 47
Baseline Total Maximal Chorea (TMC) score:
- 12
Age:
- 45
CAG repeat length:
- 47
Baseline Total Maximal Chorea (TMC) score:
- 12
INGREZZA treatment resultsb:
- Change in TMC score from Baseline to Week 12: –9
Note: Not all movements may be visible in these videos
Michelle
Age:
- 56
CAG repeat length:
- 42
Baseline Total Maximal Chorea (TMC) score:
- 9
Age:
- 56
CAG repeat length:
- 42
Baseline Total Maximal Chorea (TMC) score:
- 9
INGREZZA treatment resultsb:
- Change in TMC score from Baseline to Week 12: –7.5
Note: Not all movements may be visible in these videos
Mary
Age:
- 58
CAG repeat length:
- 44
Baseline Total Maximal Chorea (TMC) score:
- 19
Age:
- 58
CAG repeat length:
- 44
Baseline Total Maximal Chorea (TMC) score:
- 19
INGREZZA treatment resultsb:
- Change in TMC score from Baseline to Week 12: –5
Note: Not all movements may be visible in these videos
Keith
Age:
- 48
CAG repeat length:
- 46
Baseline Total Maximal Chorea (TMC) score:
- 15
Age:
- 48
CAG repeat length:
- 46
Baseline Total Maximal Chorea (TMC) score:
- 15
INGREZZA treatment resultsb:
- Change in TMC score from Baseline to Week 12: –4
Note: Not all movements may be visible in these videos
Patricia
Age:
- 58
CAG repeat length:
- 42
Baseline Total Maximal Chorea (TMC) score:
- 13
Age:
- 58
CAG repeat length:
- 42
Baseline Total Maximal Chorea (TMC) score:
- 13
INGREZZA treatment resultsb:
- Change in TMC score from Baseline to Week 12: –4
Note: Not all movements may be visible in these videos
Linda
Age:
- 70
CAG repeat length:
- 40
Baseline Total Maximal Chorea (TMC) score:
- 9
Age:
- 70
CAG repeat length:
- 40
Baseline Total Maximal Chorea (TMC) score:
- 9
INGREZZA treatment resultsb:
- Change in TMC score from Baseline to Week 12: –3
Note: Not all movements may be visible in these videos
Alan
Age:
- 40
CAG repeat length:
- 48
Baseline Total Maximal Chorea (TMC) score:
- 9
Age:
- 40
CAG repeat length:
- 48
Baseline Total Maximal Chorea (TMC) score:
- 9
INGREZZA treatment resultsb:
- Change in TMC score from Baseline to Week 12: –2
Note: Not all movements may be visible in these videos
These patients provided consent to allow Neurocrine Biosciences to use these videos and their protected health information. |
|
| a | The KINECT-HD pivotal study was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of once-daily INGREZZA in subjects with HD chorea. The study included a 4-week screening period, an 8-week dose-adjustment period, a 4-week maintenance period, and a final study visit 2 weeks following the last dose of study drug. If the subject did not tolerate the current dose, the investigator could decrease the subject’s dose at any time during the dose adjustment period, which included Week 8. The primary efficacy endpoint was the change in Total Maximal Chorea score based on on-site assessments from baseline (the average of the screening and Day –1 assessments) to the average of the Week 10 and Week 12 assessments.1 |
| b | This result reflects only the change in TMC score from Baseline to Week 12, which differs from the design of the KINECT-HD study. |
THERAPEUTIC DOSE FROM DAY 1
The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1
EXPLORE DOSINGREVIEW EFFICACY IN HD CHOREA
Explore how INGREZZA reduced HD chorea severity in the KINECT-HD pivotal study
VISIT EFFICACY IN HD CHOREACONNECT WITH A REPRESENTATIVE
Request an office visit from a Neurocrine representative for additional information, patient resources, or samples of INGREZZA
REQUEST INFOREFERENCES:
- Furr Stimming E, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6):494-504.
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.